Injection, carfilzomib, 1 mg
Products billed under this code include Kyprolis.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Kyprolis.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Kyprolis | Amgen Inc | 76075-0101-01 | 60 | $3,623.46 |
| Kyprolis | Amgen Inc | 76075-0101-21 | 60 | $3,623.46 |
| Kyprolis | Amgen Inc | 76075-0102-01 | 30 | $1,811.73 |
| Kyprolis | Amgen Inc | 76075-0102-21 | 30 | $1,811.73 |
| Kyprolis | Amgen Inc | 76075-0103-01 | 10 | $603.91 |
| Kyprolis | Amgen Inc | 76075-0103-21 | 10 | $603.91 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $60.391 | +$0.10 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $60.291 | +$4.052 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $56.239 | +$0.632 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $55.607 | −$0.04 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $55.647 | +$0.557 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $55.09 | +$3.243 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $51.847 | −$0.118 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $51.965 | +$2.388 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $49.577 | −$0.052 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $49.629 | +$2.45 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $47.179 | +$0.094 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $47.085 | +$0.188 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $46.897 | −$0.143 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $47.04 | +$2.276 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted June 5, 2024 |
| 2Q23 | $44.764 | −$0.297 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted February 23, 2024 |
| 1Q23 | $45.061 | +$1.034 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted December 6, 2023 |
| 4Q22 | $44.027 | +$0.785 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted June 22, 2023 |
| 3Q22 | $43.242 | +$1.907 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted June 9, 2023 |
| 2Q22 | $41.335 | +$0.224 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted December 14, 2022 |
| 1Q22 | $41.111 | +$0.008 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted June 8, 2022 |
| 4Q21 | $41.103 | +$0.621 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted June 2, 2022 |
| 3Q21 | $40.482 | +$1.358 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted June 2, 2022 |
| 2Q21 | $39.124 | −$0.221 | 1 MG | Injection, carfilzomib, 1 mg | v1, posted March 1, 2022 |
| 1Q21 | $39.345 | – | 1 MG | Injection, carfilzomib, 1 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.